Search jobs Johnson & Johnson Single-Shot COVID-19 Vaccine Phase 3 Data Published in New England Journal of Medicine
NEW BRUNSWICK, N.J., April 21, 2021 – Johnson & Johnson (the Company) today announced publication in the New England Journal of Medicine of primary data from the Phase 3 ENSEMBLE clinical trial for its single-dose COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen). The publication of the primary analysis follows the topline efficacy and safety data announced in January, showing the trial met all primary and key secondary endpoints, and found that the Johnson & Johnson single-dose COVID-19 vaccine prevented hospitalization and death across all study participants 28 days after vaccination.
Arts Consulting Group Seeking New Leader for Bennington Museum huntscanlon.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from huntscanlon.com Daily Mail and Mail on Sunday newspapers.